Strategies for antigen loading of dendritic cells to enhance the antitumor immune response.
Scott E. Strome(Northwestern Medicine Lake Forest Hospital), Lieping Chen(Yale Cancer Center), Jun Lü(Yale Cancer Center), Ryan A. Wilcox(University of Michigan), Dallas B. Flies(Mayo Clinic in Arizona), Tamekia L. Wakefield, Richard G. Vile(Mayo Clinic), Stephen G. Voss, Jan L. Kasperbauer(Mayo Clinic), Dennis A. Gastineau, Douglas Padley(Mayo Clinic), Andrei I. Chapoval(Human Genome Sciences (United States)), Peter J. Wettstein, Koji Tamada(Yamaguchi University)
PubMed
March 15, 2002
Cited by 154
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
|Nature Medicine|2002|5.1k
Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
|Journal of Clinical Investigation|2015|1.4k
B7-H3: A costimulatory molecule for T cell activation and IFN-γ production
|Nature Immunology|2001|1k
The anxiolytic effect of Bifidobacterium longum NCC3001 involves vagal pathways for gut-brain communication
|Neurogastroenterology & Motility|2011|1k